IMP3

Across TCGA pan-cancer cohorts, IMP3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IMP3 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IMP3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IMP3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where IMP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	1.000	0.342	.007	17	view →
CCRCC	DFS	Tertile	All	0.474	0.879	.017	15	view →
HNSC	OS	Median	All	0.344	1.000	.009	14	view →
LSCC	DFS	Median	II,III,IV	0.861	0.512	.003	11	view →
PDAC	OS	Median	All	0.675	0.478	.012	9	view →
UCEC	DFS	Median	All	0.933	1.000	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IMP3–LUAD (OS)

Open the LUAD breakdown →